The OIC-Secretary of Health (SOH) approves the HTA Council recommendation on the government financing of apixaban, dabigatran, and rivaroxaban for the prevention of myocardial infarction, cerebrovascular diseases and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroups of NVAF patients through their inclusion in the Philippine National Formulary, effective as of 25 April 2023.

We shall share the Department of Health’s circular once available.

Evidence Summary:

To keep updated on HTA news, visit our website:
Like and follow our FB page: